SCHEMBL7145371

SCHEMBL7145371

Cc1ccc(N(C2CCN(Cc3ccccc3)CC2)S(=O)(=O)c2ccc3ccccc3c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
KMT2A Q03164 2/20 0.54
CCR4 P51679 4/20 0.54
KDM4E B2RXH2 1/20 0.53
BCL2L1 Q07817 1/20 0.48
MCL1 Q07820 1/20 0.48
BCHE P06276 1/20 0.48
DRD4 P21917 1/20 0.47
LMNA P02545 2/20 0.46
USP2 O75604 1/20 0.46
HTR7 P34969 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TSHR P16473 1/20 0.44
CNR2 P34972 1/20 0.43
ACHE P22303 1/20 0.43
BACE1 P56817 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142247 0.88 NPSR1 (0.56) ALDH1A1SMN1; SMN2LMNANPSR1TSHR
SCHEMBL7166030 0.86 CHRM2 (0.57) ALDH1A1KMT2AKDM4EDRD4LMNA
SCHEMBL7142524 0.85 CHRM2 (0.49) ALDH1A1KMT2AKDM4EDRD4TSHR
SCHEMBL7139303 0.84 CHRM2 (0.55) ALDH1A1SMN1; SMN2KMT2ACCR4KDM4E
SCHEMBL7198828 0.82 BCHE (0.50) SMN1; SMN2BCHELMNANPSR1HTT
SCHEMBL7141686 0.81 CHRM2 (0.61) ALDH1A1KMT2AKDM4ELMNATSHR
SCHEMBL7167171 0.80 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KMT2ACCR4KDM4E
SCHEMBL7147151 0.80 HTR2A (0.58) KMT2AACHE
SCHEMBL7149783 0.78 ACHE (0.54) ALDH1A1KMT2AKDM4ELMNATSHR
SCHEMBL7251853 0.78 CHRM3 (0.45) BCHEACHEBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP claimed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 ALDH1A1 1218/4885SMN1; SMN2 2611/4885KMT2A 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.